Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
-0.05 (-0.82%)
Sep 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.98 - 6.10
52 week 5.05 - 7.45
Open 6.05
Vol / Avg. 3,533.00/9,416.00
Mkt cap 74.47M
P/E     -
Div/yield     -
EPS -0.71
Shares 12.31M
Beta 1.23
Inst. own 31%
Sep 12, 2017
Chembio Diagnostics Inc at Rodman & Renshaw Global Investment Conference
Aug 9, 2017
Q2 2017 Chembio Diagnostics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -52.81% -74.69%
Operating margin -53.00% -42.37%
EBITD margin - -36.00%
Return on average assets -43.06% -64.49%
Return on average equity -53.20% -76.64%
Employees 131 -
CDP Score - -


3661 Horseblock Rd
MEDFORD, NY 11763-2215
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

Officers and directors

Sharon Klugewicz Acting Chief Executive Officer
Age: 49
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Javan Esfandiari Chief Science and Technology Officer
Age: 48
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 52
Bio & Compensation  - Reuters
Paul Lambotte Ph.D. Vice President - Product Development
Age: 64
Bio & Compensation  - Reuters
Michael K. Steele Vice President - Business Development, Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Katherine L. Davis Non-Executive Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Gail S. Page Director
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Gary Meller M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters